‘London to Manchester’ sounds like the title to a biography of footballer Robin van Persie, but is, in fact, a description of Proactive Investors’ exciting events schedule in the final week of June.
Ariana Resources' (LON:AAU) Red Rabbit project in Turkey is one of the most keenly followed gold projects being carried out by a junior. Headed by an experienced board, the firm hopes to soon transform into the ranks of gold producer. The company recently inked a £1.25mln subscription and equity swap agreement with Lanstead Capital.
Seeing Machines (LON:SEE) has some very clever technology that enables machines to see and track human faces and certain facial features. The company’s recently announced deal with US mining truck titan Caterpillar was a real eye-opener, and a massive endorsement of the company’s driver fatigue monitoring system. With some 38,000 Caterpillar mining vehicles in operation around the world, the deal clearly opens up a significant market for the system, which is sold for around US$10,000.
‘Seeing is believing,’ as the old adage has it, so come along and check out this and the other two exciting growth stories.
The following day, June 26, at the Midland Hotel, Peter Street, in Manchester, has a healthcare theme, with two cutting-edge drug developers and the maker of a piece of kit that holds the key to saving the NHS hundreds of millions of pounds a year.
Initially, the target will be prostate cancer, but there may be the opportunity to broaden its scope. Initial results from the trial are due by the end of the year.
ValiRx’s plan is a smart one: to take VAL 201 along the value chain and part way through the clinical trial process before then finding a partner that will shoulder the financial and clinical risk that comes with later stage development of a drug.
With the share price up 34% over the last month, you sense the tide could be turning for Deltex Medical (LON:DEMG), the inventor of the revolutionary CardioQ-ODM system.
The device changes the way doctors care for surgical patients allowing them to recover faster and leave hospital sooner and in better health than they otherwise would do.
In bald terms CardioQ has the potential to save cash-strapped healthcare providers such as the NHS huge amounts of money annually.
For e-Therapeutics (LON:ETX), the Oxford and Newcastle-based pioneer of network pharmacology, the funding silver bullet was fired in March when it successfully concluded a £40mln cash call.
The primary goal is to bankroll the development of cancer treatment ETS2101 through further trials, including a proof-of-concept phase II study in its lead indication of glioma, a type of brain tumour. Around £25 mln has been earmarked to pursue the principal glioma indication, together with four to six additional solid tumour indications.
All events start at 6pm prompt and after the presentations, directors will take questions during a free canapé and wine reception.